🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

So great to have DrBagrodia join us for #UOB Grand Rounds this am. Fantastic #germcelltumor overview.

In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity. The likelihood of a response was higher in hereditary cases than in sporadic ones. Full study results: nej.md/44aWRDP

We are PUMPED to have Tony join the #UOB.

We could not be more thrilled with this year’s #suomatch YUO Society of Urologic Oncology *Tony Su Tony Su The Johns Hopkins Brady Urological Institute *Moh Amed Mohamed Ahmed Mayo Clinic Urology *Anis Assad Anis Assad Université de Montréal #dreamteam

Incredibly grateful for The Johns Hopkins Brady Urological Institute mentors & colleagues and excited for the opportunity! Christian Pavlovich Max Kates Mohamad Allaf Sunil Patel MD Arvin K. George, MD Misop Han Hiten Patel Phillip Pierorazio Brian Shuch, MD

Thrilled to share that Mohamed Ahmed is heading to the nick for Society of Urologic Oncology fellowship in Urologic Oncology! They’re getting an incredible surgeon, scientist, and human being. #SUOMatch #UroTwitter #UrologicOncology #NCI nick Mark Ball, MD, FACS Peter Pinto Society of Urologic Oncology YUO

Thrilled to be joining the NIH for a fellowship in Urologic Oncology! Honored to become part of this incredible team. Endless thanks to my mentors, colleagues, and family for their unwavering support. Université de Montréal #UroOnc #NIH Society of Urologic Oncology

Congrats to the ⁦National Cancer Institute⁩ Team on this landmark paper in HLRCC! It sets the SOC in this rare kidney cancer variant. ⁦NEJM⁩ ⁦NCI Surgical Oncology⁩ ⁦NCI CCR GU Malignancies⁩ nejm.org/doi/full/10.10…

Excited to share our work performed at National Cancer Institute addressing needs of rare hereditary kidney cancer through bench to bedside work Bevacizumab + erlotinib for #HLRCC assoc RCC 📍Response rate 72% 📍mPFS 21.1 mo Thanks to the patients who supported the study! nejm.org/doi/full/10.10…

Nice Xtorial, Sandeep Gurram 👇

VHL-associated RCC is not indolent. We need better than surveillance. European Urology European Association of Urology (EAU) Amer. Urol. Assn. ESMO - Eur. Oncology ASCO VHL Alliance KidneyCAN IKCC Kidney Cancer Kidney Cancer National Cancer Institute Mark Ball, MD, FACS OncoAlert Oncology Brothers doi.org/10.1016/j.euru…

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer out on NEJM nejm.org/doi/full/10.10… In a phase 2 open-label study, the combination of bevacizumab and erlotinib demonstrated notable antitumor activity in patients with advanced hereditary

July is always a bittersweet month, saying goodbye and good luck to our fellows. Will miss these three excellent surgeon-scientists:

Also very proud of this year's kidney cancer research team - post-bacc Lauren Loebach , #MRSP Milan Patel medical student, and three SUO fellows Ruben Blachman Braun Braden Millan Jas Saini, MD FRCSC

#KCRS25 Session 2 explored how genetic screening, imaging, and risk assessment can guide smarter screening strategies for kidney cancer. Screening Those with Hereditary Risk with Maria Carlo Novel Imaging Tools for Early Detection with Mark Ball, MD, FACS Screening After Negative

Congratulation to Dr. Marston Linehan on receiving the inaugural Kidney Cancer Hall of Fame award from KidneyCAN at #KCRS25. A mentor to many of us and an inspiration to all in the kidney cancer community.

#KCRS25 is an amazing meeting for many reasons, but watching an illustrator draw your talk as you give it very cool.

That's a wrap on #KCRS25! Thank you to everyone who joined us, whether you were with us in Boston or tuning in virtually from around the world. Your presence, questions, and passion for collaboration made this year’s summit one to remember. Until next time, keep pushing the

New edition of Campbell’s has arrived, with touching tribute to Alan Partin. Elsevier The Johns Hopkins Brady Urological Institute